Prime Medicine, Inc.

PRME · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
65
SEC Filings

Business Summary

PART I Overview We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prim...

Next Earnings

Q2 FY2026 — expected 2026-09-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionPRMEdiscussed_in_filing Cybersecurity
topic_mentionPRMEdiscussed_in_filing Trusted Computing
topic_mentionPRMEdiscussed_in_filing Blockchain & Crypto
topic_mentionPRMEdiscussed_in_filing Regulation
topic_mentionPRMEdiscussed_in_filing Automotive
topic_mentionPRMEdiscussed_in_filing Healthcare & Bio
topic_mentionPRMEdiscussed_in_filing AI Compute
topic_mentionPRMEdiscussed_in_filing Platform & Ecosystem
topic_mentionPRMEdiscussed_in_filing Sovereign & Government
topic_mentionPRMEdiscussed_in_filing Cybersecurity
topic_mentionPRMEdiscussed_in_filing Trusted Computing
topic_mentionPRMEdiscussed_in_filing Blockchain & Crypto
topic_mentionPRMEdiscussed_in_filing Regulation
topic_mentionPRMEdiscussed_in_filing Automotive
topic_mentionPRMEdiscussed_in_filing Healthcare & Bio
topic_mentionPRMEdiscussed_in_filing AI Compute
topic_mentionPRMEdiscussed_in_filing Platform & Ecosystem
topic_mentionPRMEdiscussed_in_filing Sovereign & Government
topic_mentionPRMEdiscussed_in_filing Cybersecurity
topic_mentionPRMEdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-032025-12-310001628280-26-013569EDGAR132K words
2025-02-282024-12-310001628280-25-008884EDGAR—
2024-03-012023-12-310001628280-24-008116EDGAR—
2023-03-092022-12-310001628280-23-007266EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001628280-25-050422EDGAR20K words
2025-08-072025-06-300001628280-25-038619EDGAR—
2025-05-082025-03-310001628280-25-023486EDGAR—
2024-11-122024-09-300001628280-24-047130EDGAR—
2024-08-082024-06-300001628280-24-035893EDGAR—
2024-05-102024-03-310001628280-24-022473EDGAR—
2023-11-032023-09-300001628280-23-036777EDGAR—
2023-08-072023-06-300001628280-23-027772EDGAR—
2023-05-112023-03-310001628280-23-017423EDGAR—
2022-11-142022-09-300001628280-22-029889EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-030001628280-26-013565EDGAR2K words
2026-01-120001628280-26-001773EDGAR—
2025-11-070001628280-25-050415EDGAR—
2025-09-080001894562-25-000056EDGAR—
2025-08-070001628280-25-038617EDGAR—
2025-08-050001628280-25-037840EDGAR—
2025-07-310001628280-25-037076EDGAR—
2025-07-300001628280-25-036705EDGAR—
2025-07-150001628280-25-034971EDGAR—
2025-06-050001628280-25-029646EDGAR—

65 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001894562
TickerPRME
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c26c686ee74d934c36a90390677d30c3a776004d7f47574bb541a1e9121603a3
parent: 3efb1e6b93eff84301151bc0d472c88e2d323d181cc8cdb9ba0ab44daffbe2e7
content hash: f37a7355450992dd461b9bed3324bfc982a4e582e81ef428443f29879274ee75
signed: 2026-04-13T04:47:00.034Z
sources: 14 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf